Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: bunn who wrote (390)	12/27/2005 12:08:31 PM
From: tuck	Read Replies (1) \| Respond to of 510

Nice numbers in this study for prostate cancer if validated: >>Asian J Androl. 2006 Jan;8(1):45-51. Application of surface-enhanced laser desorption/ionization time-of-flight-based serum proteomic array technique for the early diagnosis of prostate cancer. Pan YZ, Xiao XY, Zhao D, Zhang L, Ji GY, Li Y, Yang BX, He DC, Zhao XJ. Research Institute of Cytobiology of Academy of Life Science, Research Institute of Proteomics, Normal University, Beijing 100875, China. Tel: +86-10-5880-9729, Fax: +86-10-5880-5042 E-mail: dhe@bnu.edu.cn. Aim: To identify the serum biomarkers of prostate cancer (PCa) by protein chip and bioinformatics. Methods: Serum samples from 83 PCa patients and 95 healthy men were taken from a mass screening in Changchun, China. Protein profiling was carried out using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS). The data of spectra were analyzed using two bioinformatics tools. Results: Eighteen serum differential proteins were identified in the PCa group compared with the control group (P < 0.01). There were four proteins at the higher serum level and 14 proteins at the lower serum level in the PCa group. A decision tree classification algorithm that used an eight-protein mass pattern was developed to correctly classify the samples. A sensitivity of 92.0 % and a specificity of 96.7 % for the study group were obtained by comparing the PCa and control groups. Conclusion: We identified new serum biomarkers of PCa. SELDI-TOF MS coupled with a decision tree classification algorithm will provide a highly accurate and innovative approach for the early diagnosis of PCa.<< Cheers, Tuck